CONTEXT: An excess circulating @entity414 level, even within the normal range, is always comorbid with @entity209 ( @entity209 ), several of its components, and @entity1561 ( @entity1561 ), which was regarded as hepatic manifestation of @entity209 ; however, these associations remain controversial. OBJECTIVE: This study aimed to quantitatively assess the relationship between the serum @entity414 (SUA) levels and the @entity209 / @entity1561 risk. DESIGN: We searched for related prospective cohort studies including SUA as an exposure and @entity209 / @entity1561 as a result in MEDLINE (PubMed) and EMBASE databases up to January 31, 2015 and July 28, 2015, respectively. Pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs) were extracted. A random-effects model was used to evaluate dose-response relationships. MAIN OUTCOMES: On the basis of 11 studies (54 970 @entity1 and 8719 @entity209 cases), a combined RR of 1.72 (95% CI, 1.45-2.03; P < .0001) was observed for the highest SUA level category compared with the lowest SUA level category. Furthermore, based on nine studies (51 249 @entity1 and 8265 @entity209 cases), dose-response analysis suggested that each 1 mg/dL SUA increment was roughly linearly associated with the @entity209 risk (RR, 1.30; 95% CI, 1.22-1.38; P < .0001). Beyond that, SUA level increased @entity1561 risk (RR, 1.46; 95% CI, 1.31-1.63). Each 1 mg/dL SUA level increment led to 21% increase in the @entity1561 risk. CONCLUSIONS: This meta-analysis suggests that higher SUA levels led to an increased risk of @entity209 regardless of the study characteristics, and were consistent with a linear dose-response relationship. In addition, SUA was also a causal factor for the @entity1561 risk.

Serum XXXX Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies.

@entity209 :: ('MESH:D008659', 'Disease') :: ['MS', 'metabolic syndrome'] @entity1 :: ('9606', 'Species') :: ['participants'] @entity1561 :: ('MESH:D065626', 'Disease') :: ['NAFLD', 'nonalcoholic fatty liver disease'] @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']
@entity414 :: (MESH:D014527,Chemical) :: ['Uric Acid']
